Iproteos launches groundbreaking equity crowdfunding campaign
The funds raised will go to study a drug to treat schizophrenia
Catalan biotechnology firm Ipotreos has launched an innovative funding campaign based on equity crowdfunding. They aim to raise €100,000 to carry out non-regulatory preclinical trails on their IPR019 compound, a drug they are developing to curb the progression and reverse cognitive impairment associated with schizophrenia.
Equity crowdfunding, or participative funding, is a new way to attract funds for projects, through which investors receive shares in the company in exchange for their contributions. Investors interested in participating in the Ipotreos equity crowdfunding can do so through the Creoentuproyecto.com platform.
The Iproteos IPR019 compound is the company’s most advanced project in terms of development. It is a latest-generation cognitive enhancer that has been proven highly effective in animal models with this disease. The compound has improved learning and memory in patients with schizophrenia, which doesn’t happen after administering the treatments currently available.
Iproteos, located in the Barcelona Science Park, is a spin-off created through transfer of general technology from the Institute for Research in Biomedicine (IRB Barcelona) and the University of Barcelona, with strategic participation from the Bosh i Gimpera Foundation.
More information is available in the press release.